Genmab — Januar 2025
-
Danske helårsregnskaber 2024: Fokus på guidance, moderat vækst og fremtidens USA https://proinvestor.com/boards/123960
-
At the recent IRT conference, Genmab USA’s IRT manager, Madeline Tremont, discussed how the company implemented IRT systems for their first-in-human (FIH) clinical trials. https://informaconnect.com/streamlining-first-in-human-trials-with-irt-systems/ What is Interactive Response Technology (IRT)? https://www.suvoda.com/insights/blog/what-is-interactive-response-technology-irt
-
Top 25 Biotech Companies Heading Into 2025 https://www.genengnews.com/industry-news/top-25-biotech-companies-heading-into-2025/ - -
will Genmab manage to get back into that list again...? -
Life Science vinderaktier 2024 – sådan gik det https://proinvestor.com/investornyt/1262130/life-science-vinderaktier-2024-sadan-gik-det
-
-
J&J's Rybrevant, Lazcluze combo significantly improves survival over Tagrisso in lung cancer https://firstwordpharma.com/story/5925447
-
quite a few cancer centers in Asia added to the Acasunlimab /Pembro Ph3 trial. maybe the local presence/office in Japan helps here. a bit surprised they still name Biontech as Collaborator. https://clinicaltrials.gov/study/NCT06635824?tab=history&a=4&b=5#version-content-panel
-
Hvordan vurderer I gårsdagens Rybrevant-data? Er de ikke ret positive? Og gør det ikke GEN1286 ekstra spændende, når den ifølge Jan er meget bedre end amivantamab i prækliniske studier?
-
Sachin Jain’s rating is based on Genmab’s promising pipeline and strategic developments. One of the key factors is the anticipated progress of the HexaBody-CD38, which is set for a critical opt-in decision by JNJ in the first quarter of 2025. This decision will determine the future of the drug, which has shown encouraging data in comparison to Darzalex in multiple myeloma.
Another significant reason for the Buy rating is the potential of Rina-S, -
-
Additionally, the strong launch of Epkinly in late-line patients and its promising expansion into larger indications further supports the Buy recommendation. The company’s confidence in managing liver toxicity issues related to Acasunlimab and the robust overall survival data add to the optimistic outlook for Genmab.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind